<p>Bayer AG has outlined its strategic focus for its Pharmaceuticals Division through 2026, emphasizing accelerated growth and expanded market presence. The company plans to drive global regulatory expansions and increase market penetration across its pharmaceutical portfolio, particularly in oncology, cardiology, and women’s health. Bayer aims to deliver multiple high-impact product launches and secure five pivotal worldwide approvals in 2025. The strategy includes advancing a modality-rich pipeline in oncology, cardiology, neurology, and immunology, supported by investments in R&amp;D, partnership-driven innovation, and AI-enabled development. Bayer intends to strengthen its position in cardiovascular and cerebrovascular medicine and maintain a commitment to commercial excellence for sustainable growth. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20260113594054) on January 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

BAYN

Reuters

Bayer AG

Bayer AG Outlines Future Pharma Strategy: Global Regulatory Expansions, High-Impact Launches, and Accelerated Pipeline Development Across Oncology, Cardiology, Neurology, and Immunology